论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
Authors Xia Y, Xu T, Wang C, Li Y, Lin Z, Zhao M, Zhu B
Received 11 August 2017
Accepted for publication 13 November 2017
Published 22 December 2017 Volume 2018:13 Pages 143—159
DOI https://doi.org/10.2147/IJN.S148960
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Alexander Kharlamov
Peer reviewer comments 5
Editor who approved publication: Dr Lei Yang
Abstract: Human
homeobox protein (Nanog) is highly expressed in most cancer cells and has
gradually emerged as an excellent target in cancer therapy, owing to its
regulation of cancer cell proliferation, metastasis and apoptosis. In this
study, we prepared tumor-targeting functionalized selenium nanoparticles
(RGDfC-SeNPs) to load chemotherapeutic doxorubicin (DOX) and Nanog siRNA.
Herein, RGDfC peptide was used as a tumor-targeting moiety which could specifically
bind to αvβ3 integrins overexpressed on various cancer cells. The sizes of
RGDfC-SeNPs@DOX nanoparticles (~12 nm) were confirmed by both dynamic light
scattering and transmission electron microscopy. The chemical structure of
RGDfC-SeNPs@DOX was characterized via Fourier-transform infrared spectroscopy.
The RGDfC-SeNPs@DOX was compacted with siRNA (anti-Nanog) by electrostatic
interaction to fabricate the RGDfC-SeNPs@DOX/siRNA complex. The
RGDfC-SeNPs@DOX/siRNA complex nanoparticles could efficiently enter into HepG2
cells via clathrin-associated endocytosis, and showed high gene transfection
efficiency that resulted in enhanced gene silencing. The in vivo
biodistribution experiment indicated that RGDfC-SeNPs@DOX/siRNA nanoparticles
were capable of specifically accumulating in the tumor site. Furthermore,
treatment with RGDfC-SeNPs@DOX/siRNA resulted in a more significant anticancer
activity than the free DOX, RGDfC-SeNPs@DOX or RGDfC-SeNPs/siRNA in vitro
and in vivo. In summary, this study shows a novel type of DOX and siRNA
co-delivery system, thereby providing an alternative route for cancer
treatment.
Keywords: nanoparticles, tumor targeting, drug delivery, doxorubicin, Nanog
siRNA